Kyntra Bio (KYNB) Cash & Current Investments (2014 - 2026)

Kyntra Bio has reported Cash & Current Investments for 13 years, with the latest figure at $37.0 million in Q1 2026.

• Quarterly Cash & Current Investments rose 350.19% year-over-year to $37.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $37.0 million (up 350.19% YoY) and the FY2025 annual result came in at $57.9 million, down 43.37% from the prior year.
• Cash & Current Investments declined to $37.0 million in Q1 2026 per KYNB's latest filing, from $57.9 million in the prior quarter.
• Over five years, Cash & Current Investments peaked at $438.1 million in Q2 2022 and troughed at $8.2 million in Q1 2025.
• A 5-year average of $199.5 million and a median of $131.0 million in 2024 frame the typical range for Cash & Current Investments.
• The sharpest annual moves came in 2025 and 2026: Cash & Current Investments sank 92.74% in 2025, then surged 350.19% in 2026.
• Over 5 years, Cash & Current Investments stood at $422.0 million in 2022, then sank by 44.17% to $235.6 million in 2023, then sank by 56.63% to $102.2 million in 2024, then tumbled by 43.37% to $57.9 million in 2025, then tumbled by 36.06% to $37.0 million in 2026.
• According to Business Quant data, Cash & Current Investments over the past three periods registered $37.0 million, $57.9 million, and $24.2 million for Q1 2026, Q4 2025, and Q3 2025 respectively.